HLA-A*24:02-URLC10 peptide complex (HLA-A*24:02-URLC10)

The HLA-A*24:02-URLC10 peptide complex is a specific molecular target consisting of the Human Leukocyte Antigen (HLA) allele A*24:02 presenting a peptide derived from the Up-regulated in Lung Cancer 10 (URLC10) protein [1]. URLC10 is a cancer-testis-like antigen that is highly expressed in various malignancies, including non-small cell lung cancer, esophageal cancer, and pancreatic cancer, while having minimal expression in normal tissues except the testis [1, 2]. The presentation of the URLC10-177 peptide (sequence: RYCNLEGPPI) by HLA-A*24:02 on the surface of tumor cells allows for recognition by specific CD8+ cytotoxic T lymphocytes (CTLs) [1]. Therapeutic strategies targeting this complex primarily involve peptide vaccines, such as the URLC10-177 component of the S-288310 cocktail, which aim to stimulate an endogenous immune response against tumor cells [2, 3]. These treatments are designed to induce CTLs that selectively lyse URLC10-positive tumor cells in patients carrying the HLA-A*24:02 allele [3]. This target is particularly relevant in East Asian populations where the HLA-A*24:02 allele is highly prevalent [2]. Safety profiles for drugs targeting this complex generally show mild adverse events, such as injection site reactions, though the therapy is strictly limited by the patient's HLA genotype [3]. Sources: [1] Suda T, et al. Cancer Sci. 2007;98(11):1803-8. [2] Watanabe T, et al. Oncol Rep. 2014;31(1):27-34. [3] Hazama S, et al. Oncol Rep. 2014;31(1):35-42.

Other names

HLA-A*24:02-URLC10-177URLC10-177/HLA-A*24:02 complexC10orf116-derived peptide-MHC complexRYCNLEGPPI-HLA-A*24:02 complex

Induction of peptide-specific cytotoxic T lymphocytes (CTLs) that recognize and lyse tumor cells presenting the URLC10 peptide via HLA-A*24:02.